Protein profiling of 40 CMD trial patient plasma

PRE-SOLICITATION NOTICE OF INTENT NON-COMPETITIVE SUBJECT Protein profiling of 40 CMD trial patient plasma REGULATORY AUTHORITY This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13—Simplified Acquisition Procedures, and the procedures prescribed in FAR Subpart 13.106-1(b)(1), Soliciting from a single source. The resultant contract will include all applicable provisions and clauses of the FAR in effect through the Federal Acquisition Circular (FAC) 2022-08, dated 10/28/2022. DESCRIPTION Pursuant to FAR Subpart 5.2—Synopses of Proposed Contract Actions, THIS IS A PRE-SOLICITATION NOTICE OF INTENT TO AWARD A CONTRACT WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION. The National Institute on Drug Abuse (NIDA), Office of Acquisition (OA), on behalf of the National Institute of Neurological Disorders and Stroke (NINDS) intends to negotiate and award a purchase order for protein profiling of 40 CMD trial patient plasma for its researchers and scientists in the Surgical Neurology Branch (SNB). The National Institutes of Health (NIH) is the nation’s leading medical research agency and the primary Federal agency whose mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability, conducting, supporting and making medical discoveries that improve people’s health and save lives. The National Institute of Neurological Disorders and Stroke (NINDS) is a part of the National Institutes of Health (NIH), which mission it is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease for all people. The SNB investigators are conducting Cytokine Microdialysis clinical trial (18-N-0077) to investigate the changes in the immune microenvironment and systemic immune system in response to checkpoint inhibition in recurrent glioblastoma patients undergoing resection.The investigators have fully enrolled 10 patients into this pilot study, as per protocol, and they are now completing one of the protocol-required assays- protein profiling of circulating proteins in patient plasma. ANTICIPATED SOURCE Company Name – SomaLogic Operating Co. Company Address – 2945 Wilderness Place Boulder, CO 80301 UEI: CTK7E4CB43M7 Delivery Raw data consisting of the quantitative level of the proteins on the Somascan assay is to be sent to the SNB in digital format within 30 days of receipt of samples. PLACE OF PERFORMANCE N/A REASON FOR NON-COMPETITIVE ACTION The essential characteristics of the 40 plasma Somascan Discovery Assay that limit the availability to a sole source are that plasma protein profiling by SomaLogic is best for the total consistency of method and data analysis. CMD trial patients’ CSF and Microdialysate samples are being profilied at CHI, NIAID with same SomaScan platform. Only this suggested source can furnish the requirements, to the exclusion of other sources, because of the reasons stated above. The indicated protein profiling is proprietary technology of SomaLogic Operating Co. CLOSING STATEMENT This synopsis is not a request for competitive proposals . All responsible sources may submit a capability statement, however, which shall be considered by the agency. Responses to this notice must include clear and convincing evidence of the offeror’s capability of fulfilling the requirement. In addition, the Unique Entity Identifier (UEI), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM). A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received by 2:00 P.M., Eastern Standard Time on June 29, 2023 . Responses must be submitted electronically to the Contract Specialist, Cassandra Conley, at [email protected]. Fax responses are not accepted.